Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
HIV Infection Primary
Interventions
DRUG

Dasatinib 70 mg

Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind

OTHER

Placebo

Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.

Trial Locations (1)

08916

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
collaborator

Spanish Clinical Research Network - SCReN

NETWORK

collaborator

IrsiCaixa

OTHER

collaborator

University of Turin, Italy

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

collaborator

Germans Trias i Pujol Hospital

OTHER

collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Fundació Institut Germans Trias i Pujol

OTHER

NCT05780073 - Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment | Biotech Hunter | Biotech Hunter